UroGen Pharma Ltd. reiterated earnings guidance for the full year 2023. For the year, company expects net product revenues from JELMYTO to be in the range of $76 million to $86 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.97 USD | -0.77% | -3.57% | -13.53% |
14/05 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
13/05 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.53% | 45Cr | |
+5.33% | 11TCr | |
+12.11% | 11TCr | |
-12.56% | 2.23TCr | |
-3.70% | 2.19TCr | |
-6.03% | 1.86TCr | |
-35.21% | 1.81TCr | |
-10.86% | 1.7TCr | |
+5.10% | 1.37TCr | |
+37.57% | 1.24TCr |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- UroGen Pharma Ltd. Reiterates Earnings Guidance for the Full Year 2023